

Resource Summary Report

Generated by [dkNET](#) on Jul 31, 2026

Goat Anti-Mouse IgG H&L (HRP)

RRID:AB_10679675

Type: Antibody

Proper Citation

Abcam Cat# ab97023, RRID:AB_10679675

Antibody Information

URL: http://antibodyregistry.org/AB_10679675

Proper Citation: Abcam Cat# ab97023, RRID:AB_10679675

Target Antigen: IgG - H&L

Host Organism: goat

Clonality: monoclonal secondary

Comments: Applications: ICC, IHC-P, ELISA, WB

Antibody Name: Goat Anti-Mouse IgG H&L (HRP)

Description: This monoclonal secondary targets IgG - H&L

Target Organism: mouse

Antibody ID: AB_10679675

Vendor: Abcam

Catalog Number: ab97023

Record Creation Time: 20250820T031048+0000

Record Last Update: 20250820T153401+0000

Ratings and Alerts

No rating or validation information has been found for Goat Anti-Mouse IgG H&L (HRP).

No alerts have been found for Goat Anti-Mouse IgG H&L (HRP).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 39 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Fiyaksel OP, et al. (2025) A bacterial host factor confines phage localization for excluding the infected compartment through cell division. *Cell reports*, 44(7), 115994.

Entezam M, et al. (2025) Enhanced antitumor immunity in breast cancer: Synergistic effects of ADAM10/ADAM17 inhibition, metabolic modulation, and camptothecin-loaded selenium nanoparticles. *International journal of pharmaceutics*, 669, 125037.

Vuong N, et al. (2025) Lactobacillus rhamnosus-derived extracellular vesicles influence calcium deposition in a model of breast cancer intraductal calcium stress. *iScience*, 28(6), 112538.

Lin YT, et al. (2025) Temporal analysis of doxorubicin-induced cardiac toxicity and hypertrophy. *NPJ systems biology and applications*, 11(1), 67.

Hu Z, et al. (2025) Apigenin attenuates the atherosclerotic lesions through enhancing selective autophagy/lipophagy and promoting RCT process. *Pharmaceutical biology*, 63(1), 387.

Pesce E, et al. (2025) In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators. *British journal of pharmacology*.

Dimari G, et al. (2025) Mesenchymal-epithelial transition reduces proliferation but increases immune evasion in tumor spheroids. *iScience*, 28(8), 113023.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Naha R, et al. (2024) SLP2 and MIC13 synergistically coordinate MICOS assembly and crista junction formation. *iScience*, 27(12), 111467.

Frumento N, et al. (2024) Neutralizing antibodies evolve to exploit vulnerable sites in the HCV envelope glycoprotein E2 and mediate spontaneous clearance of infection. *Immunity*, 57(1), 40.

Scala M, et al. (2024) De novo variants in DENND5B cause a neurodevelopmental disorder. *American journal of human genetics*, 111(3), 529.

Damiecki M, et al. (2024) Mitochondrial apolipoprotein MIC26 is a metabolic rheostat regulating central cellular fuel pathways. *Life science alliance*, 7(12).

Li LY, et al. (2023) Chlorogenic acid alleviates hypoxic-ischemic brain injury in neonatal mice. *Neural regeneration research*, 18(3), 568.

Terlizzi V, et al. (2023) Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR Modulators. *International journal of molecular sciences*, 24(7).

Sweeney K, et al. (2023) Transcription factor localization dynamics and DNA binding drive distinct promoter interpretations. *Cell reports*, 42(5), 112426.

Heath BR, et al. (2023) Saturated fatty acids dampen the immunogenicity of cancer by suppressing STING. *Cell reports*, 42(4), 112303.

Maneix L, et al. (2022) Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 (HDAC3) Stabilization and Chromatin Condensation. *Cancer research communications*, 2(12), 1693.

Sondo E, et al. (2022) The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs. *International journal of molecular sciences*, 23(6).

Golomidov IM, et al. (2022) Reduction of the α -synuclein expression promotes slowing down early neuropathology development in the *Drosophila* model of Parkinson's disease. *Journal of neurogenetics*, 36(1), 1.

Baldassarri M, et al. (2022) Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes. *Cells*, 11(24).